Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation

K. Buser, M. Bacchi, A. Goldhirsch, R. Greiner, P. Diener, C. Sessa, W. F. Jungi, M. Forni, S. Leyvraz, V. Engeler

Research output: Contribution to journalArticlepeer-review


Background: The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) - and advanced (FIGO III-IV stage ovarian cancer with a surgery plus 4 cycles of cisplatin and melphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy. Patients and methods: 218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm i.v. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accelerator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease. Results: 146/218 patients (67%, 95% CI: 61%-73%) responded to PAMP: 56 (26%) achieved pCR, 24 (11%), cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TTF) and survival. Only 51/118 (43%) patients in remission received WAR. Early-stage patients

Original languageEnglish
Pages (from-to)65-70
Number of pages6
JournalAnnals of Oncology
Issue number1
Publication statusPublished - Jan 1996


  • Advanced ovarian cancer
  • Chemotherapy
  • Cisplatin
  • Melphalan
  • Second-look surgery
  • Whole abdominal radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation'. Together they form a unique fingerprint.

Cite this